Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[The goal of the current investigation was to examine a cohort of symptomatic and asymptomatic LRRK2 mutation carriers, in order to address whether the reported alterations in amyloid ? (A?) and tau species in the CSF of patients with sporadic Parkinson disease (PD) are a part of PD pathogenesis, the aging process, or a comorbid disease in patients with PD, and to explore the possibility of A? and tau as markers of early or presymptomatic PD.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• assertion description "[The goal of the current investigation was to examine a cohort of symptomatic and asymptomatic LRRK2 mutation carriers, in order to address whether the reported alterations in amyloid ? (A?) and tau species in the CSF of patients with sporadic Parkinson disease (PD) are a part of PD pathogenesis, the aging process, or a comorbid disease in patients with PD, and to explore the possibility of A? and tau as markers of early or presymptomatic PD.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[The goal of the current investigation was to examine a cohort of symptomatic and asymptomatic LRRK2 mutation carriers, in order to address whether the reported alterations in amyloid ? (A?) and tau species in the CSF of patients with sporadic Parkinson disease (PD) are a part of PD pathogenesis, the aging process, or a comorbid disease in patients with PD, and to explore the possibility of A? and tau as markers of early or presymptomatic PD.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP946812.RAe6neASyQ5wCxVHCc85EwGRCDfvwxdbMCIMUyZLeJqfE130_assertion description "[The goal of the current investigation was to examine a cohort of symptomatic and asymptomatic LRRK2 mutation carriers, in order to address whether the reported alterations in amyloid ? (A?) and tau species in the CSF of patients with sporadic Parkinson disease (PD) are a part of PD pathogenesis, the aging process, or a comorbid disease in patients with PD, and to explore the possibility of A? and tau as markers of early or presymptomatic PD.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP946812.RAe6neASyQ5wCxVHCc85EwGRCDfvwxdbMCIMUyZLeJqfE130_provenance.
• NP946811.RAjEr6iKclCa1LpQGEkaQaFn4p-U-5kt7Xol-ncp2k3fw130_assertion description "[The goal of the current investigation was to examine a cohort of symptomatic and asymptomatic LRRK2 mutation carriers, in order to address whether the reported alterations in amyloid ? (A?) and tau species in the CSF of patients with sporadic Parkinson disease (PD) are a part of PD pathogenesis, the aging process, or a comorbid disease in patients with PD, and to explore the possibility of A? and tau as markers of early or presymptomatic PD.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP946811.RAjEr6iKclCa1LpQGEkaQaFn4p-U-5kt7Xol-ncp2k3fw130_provenance.
• NP530965.RA56B3LfFBqx7vEwUXIorv28Gz0LcgpOoFz8BIS9stNtA130_assertion description "[The goal of the current investigation was to examine a cohort of symptomatic and asymptomatic LRRK2 mutation carriers, in order to address whether the reported alterations in amyloid ? (A?) and tau species in the CSF of patients with sporadic Parkinson disease (PD) are a part of PD pathogenesis, the aging process, or a comorbid disease in patients with PD, and to explore the possibility of A? and tau as markers of early or presymptomatic PD.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP530965.RA56B3LfFBqx7vEwUXIorv28Gz0LcgpOoFz8BIS9stNtA130_provenance.
• NP330727.RAPhlJL9HzzAWNqaaI0CvhFjFfedeg0TcdYIpOI4d8B7Q130_assertion description "[The goal of the current investigation was to examine a cohort of symptomatic and asymptomatic LRRK2 mutation carriers, in order to address whether the reported alterations in amyloid ? (A?) and tau species in the CSF of patients with sporadic Parkinson disease (PD) are a part of PD pathogenesis, the aging process, or a comorbid disease in patients with PD, and to explore the possibility of A? and tau as markers of early or presymptomatic PD.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP330727.RAPhlJL9HzzAWNqaaI0CvhFjFfedeg0TcdYIpOI4d8B7Q130_provenance.
• NP946813.RA1JHoMwdx_ZPPK6-QA1nPS9oKc5wVCSXBcBr6wUQ6XkY130_assertion description "[The goal of the current investigation was to examine a cohort of symptomatic and asymptomatic LRRK2 mutation carriers, in order to address whether the reported alterations in amyloid ? (A?) and tau species in the CSF of patients with sporadic Parkinson disease (PD) are a part of PD pathogenesis, the aging process, or a comorbid disease in patients with PD, and to explore the possibility of A? and tau as markers of early or presymptomatic PD.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP946813.RA1JHoMwdx_ZPPK6-QA1nPS9oKc5wVCSXBcBr6wUQ6XkY130_provenance.